{"title":"IBS-IBD条件下发酵酵母的抗炎作用","authors":"T. Archer","doi":"10.37191/mapsci-2582-6549-3(1)-032","DOIUrl":null,"url":null,"abstract":"In order to assess the anti-inflammatory and therapeutic action of the probiotic, treated-yeast Milmed, twelve patients (age range 25-to-79 years) presenting IBS-IBD with a wide range of gut-intestinal symptoms, were studied. Each patient completed a questionnaire outlining demographic characteristics and test items regarding their health issues, both prior to and after the twelve-week period (on three occasions each week) of Milmed intervention. Patients’ accounts of their symptom-profiles were quantified and subjected to statistical analyses. It was observed that in comparison with the placebo (administered untreated-yeast) control, the Milmed group reported fewer symptoms, following treatment, as well as also fewer symptoms compared to their pre-treatment report. Untreated-yeast administration to patients did not induce any reduction of IBS-IBD symptoms. There was no correlation between patients’ responses regarding symptoms Before and After intervention. It is possible that increasing the number of capsules ingested per week, from 3/week to 1/day, may have provided the patients with greater benefits. Despite certain limitations of this study when taken together with the reported anti-inflammatory propensity of Milmed upon glial and neuronal cell cultures in vitro, these findings imply several useful therapeutic applications for the treated-yeast, Milmed, in the treatment of gut-intestinal conditions, such as IBS-IBD and other related ailments.","PeriodicalId":15543,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2022-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Anti-inflammatory Action of the Treated-Yeast, Milmed, Under IBS-IBD Conditions\",\"authors\":\"T. Archer\",\"doi\":\"10.37191/mapsci-2582-6549-3(1)-032\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to assess the anti-inflammatory and therapeutic action of the probiotic, treated-yeast Milmed, twelve patients (age range 25-to-79 years) presenting IBS-IBD with a wide range of gut-intestinal symptoms, were studied. Each patient completed a questionnaire outlining demographic characteristics and test items regarding their health issues, both prior to and after the twelve-week period (on three occasions each week) of Milmed intervention. Patients’ accounts of their symptom-profiles were quantified and subjected to statistical analyses. It was observed that in comparison with the placebo (administered untreated-yeast) control, the Milmed group reported fewer symptoms, following treatment, as well as also fewer symptoms compared to their pre-treatment report. Untreated-yeast administration to patients did not induce any reduction of IBS-IBD symptoms. There was no correlation between patients’ responses regarding symptoms Before and After intervention. It is possible that increasing the number of capsules ingested per week, from 3/week to 1/day, may have provided the patients with greater benefits. Despite certain limitations of this study when taken together with the reported anti-inflammatory propensity of Milmed upon glial and neuronal cell cultures in vitro, these findings imply several useful therapeutic applications for the treated-yeast, Milmed, in the treatment of gut-intestinal conditions, such as IBS-IBD and other related ailments.\",\"PeriodicalId\":15543,\"journal\":{\"name\":\"Journal of Cutaneous Immunology and Allergy\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2022-08-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cutaneous Immunology and Allergy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37191/mapsci-2582-6549-3(1)-032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37191/mapsci-2582-6549-3(1)-032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ALLERGY","Score":null,"Total":0}
Anti-inflammatory Action of the Treated-Yeast, Milmed, Under IBS-IBD Conditions
In order to assess the anti-inflammatory and therapeutic action of the probiotic, treated-yeast Milmed, twelve patients (age range 25-to-79 years) presenting IBS-IBD with a wide range of gut-intestinal symptoms, were studied. Each patient completed a questionnaire outlining demographic characteristics and test items regarding their health issues, both prior to and after the twelve-week period (on three occasions each week) of Milmed intervention. Patients’ accounts of their symptom-profiles were quantified and subjected to statistical analyses. It was observed that in comparison with the placebo (administered untreated-yeast) control, the Milmed group reported fewer symptoms, following treatment, as well as also fewer symptoms compared to their pre-treatment report. Untreated-yeast administration to patients did not induce any reduction of IBS-IBD symptoms. There was no correlation between patients’ responses regarding symptoms Before and After intervention. It is possible that increasing the number of capsules ingested per week, from 3/week to 1/day, may have provided the patients with greater benefits. Despite certain limitations of this study when taken together with the reported anti-inflammatory propensity of Milmed upon glial and neuronal cell cultures in vitro, these findings imply several useful therapeutic applications for the treated-yeast, Milmed, in the treatment of gut-intestinal conditions, such as IBS-IBD and other related ailments.